Showing results (1-10 of 654) with videos related to

Sort By:
Pageof 66
Respiratory Research|June 29, 2021
Efficacy of budesonide/glycopyrronium/formoterol metered dose inhaler in patients with COPD: post-hoc analysis from the KRONOS study excluding patients with airway reversibility and high eosinophil countsShigeo Muro, Hisatoshi Sugiura, Patrick Darken, et al.
International Journal of Chronic Obstructive Pulmonary Disease|February 5, 2021
Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Improves Exacerbation Outcomes in Patients with COPD without a Recent Exacerbation History: A Subgroup Analysis of KRONOSFernando J Martinez, Gary T Ferguson, Eric Bourne, et al.
Therapeutic Advances in Respiratory Disease|August 25, 2021
Improvements in lung function with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler versus dual therapies in patients with COPD: a sub-study of the ETHOS trialKlaus F Rabe, Fernando J Martinez, Dave Singh, et al.
International Journal of Chronic Obstructive Pulmonary Disease|December 13, 2022
Benefits of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate on COPD Exacerbations, Lung Function, Symptoms, and Quality of Life Across Blood Eosinophil Ranges: A Post-Hoc Analysis of Data from ETHOSMona Bafadhel, Klaus F Rabe, Fernando J Martinez, et al.
Therapeutic Advances in Respiratory Disease|July 11, 2022
Predictive modeling of COPD exacerbation rates using baseline risk factorsDave Singh, John R Hurst, Fernando J Martinez, et al.
Respiratory Medicine|June 25, 2021
Benefits of budesonide/glycopyrrolate/formoterol fumarate (BGF) on symptoms and quality of life in patients with COPD in the ETHOS trialFernando J Martinez, Klaus F Rabe, Gary T Ferguson, et al.
Pulmonary Pharmacology & Therapeutics|March 17, 2018
The pharmacokinetics of three doses of budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler compared with active controls: A Phase I randomized, single-dose, crossover study in healthy adultsPatrick Darken, Paolo DePetrillo, Colin Reisner, et al.
Clinical Therapeutics|April 8, 2020
Relative Bioavailability of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Administered With and Without a Spacer: Results of a Phase I, Randomized, Crossover Trial in Healthy AdultsPaul Dorinsky, Paolo DePetrillo, Kiernan DeAngelis, et al.
Pulmonary Pharmacology & Therapeutics|December 17, 2019
Pharmacokinetics of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler formulated using co-suspension delivery technology after single and chronic dosing in patients with COPDLeonard J Dunn, Edward M Kerwin, Kiernan DeAngelis, et al.
The Lancet. Respiratory Medicine|September 21, 2018
Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trialGary T Ferguson, Klaus F Rabe, Fernando J Martinez, et al.
Pageof 66